Could MRONJ Be Related to Osimertinib Monotherapy in Lung Cancer Patients after Denosumab Suspension?

• Published in: Healthcare (Basel) Vol. 12; no. 4; p. 457
• Main Authors: Forte, Marta, d'Amati, Antonio, Limongelli, Luisa, Corsalini, Massimo, Favia, Gianfranco, Ingravallo, Giuseppe, Barile, Giuseppe, Capodiferro, Saverio
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.02.2024
• Subjects: Bone diseases; Bones; Cancer therapies; Complications and side effects; Denosumab; Drug dosages; Drug therapy; Fistula; Jaw; jaws; Lung cancer; Maxillofacial surgery; Medical imaging; Medical research; Medicine, Experimental; Metastasis; MRONJ; Necrosis; Osimertinib; Patients; prevention; Surgeons; Teeth; Italy; lung cancer; jaws; MRONJ; oral cavity; Osimertinib; Denosumab; prevention
• ISSN: 2227-9032; 2227-9032
• DOI: 10.3390/healthcare12040457

Medication-related osteonecrosis of the jaws is the most frequent complication in patients treated or in therapy with antiresorptive/antiangiogenetic drugs. The list of medications possibly related to MRONJ onset is constantly growing; we aimed to report on a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (Osimertinib) as possibly responsible for bilateral maxillary necrosis onset in the herein-described case. In June 2023, an oncologic patient with two different maxillary bone exposures was referred to our attention. His medical history revealed a two-year Denosumab regimen along with Osimertinib, the latter not suspended before teeth extractions. The clinicians performed a sequestrum removal and bone debridement after three cycles of antibiotic therapy. Histologic examinations confirmed the clinical diagnosis of MRONJ excluding a metastatic occurrence, while complete mucosal healing was achieved after 15 days. The patient suspended Denosumab for more than six months before teeth extraction for MRONJ prevention; hence, failure to discontinue Osimertinib led us to consider it a possible etiological factor. From a literature analysis, only one case has already been published reporting a possible Osimertinib-related occurrence of MRONJ in lung cancer patients. Our case is a further report that could be intended as an alert both for oncologists and dentists to share decisions about the oral management of such patients together, also informing them about this possible risk. Also, this report could trigger in the scientific community the necessity to evaluate further guidelines for similar doubtful cases in which the drug interaction, the mono-suspension, and the possible removable prosthesis-related additional trauma should be considered causes or con-causes.